

**ANTIMICROBIAL SUSCEPTIBILITY PROFILE (01/01/2023 to 12/31/2023)**  
**MedStar Union Memorial Hospital**

Gram Negative Organisms	Number of Isolates	Percent Susceptible																	
		Amikacin***	Ampicillin	Ampicillin/subbactam	Aztreonam	Cefazolin (Systemic <sup>1</sup> )	Cefazolin (Urine <sup>2</sup> )	Cefepime	Ceftriaxone	Ciprofloxacin	ESBL (Negative)	Gentamicin***	Levofloxacin	Meropenem	Nitrofurantoin*	Piperacillin/tazobactam	Tetracycline	Tobramycin***	Trimethoprim/Sulfa
<i>Acinetobacter baumannii</i> **	139	56	-	47	-	-	-	36	26	28	-	38	-	16	-	-	-	48	-
<i>Enterobacter cloacae</i>	84	100	-	-	81	-	89	77	86	-	98	-	98	0	82	93	84	94	
<i>Escherichia coli</i>	773	100	43	50	86	43	84	86	67	86	88	-	99	98	97	73	87	69	
<i>Klebsiella pneumoniae</i> ssp pneumoniae	253	99	0	62	76	54	75	76	74	77	93	-	96	44	87	69	91	72	
<i>Proteus mirabilis</i>	104	96	82	84	95	0	86	93	90	68	-	90	-	0	99	0	89	83	
<i>Pseudomonas aeruginosa</i>	219	100	-	-	66	-	-	81	-	67	-	-	77	-	69	-	98	-	
<i>Serratia marcescens</i> **	108	100	5	1	97	-	-	95	79	94	-	100	-	95	-	96	-	82	85
<i>Stenotrophomonas maltophilia</i> **	98	-	-	-	-	-	-	-	-	-	-	76	-	-	-	-	-	-	99

Gram Positive Organisms	Number of Isolates	Percent Susceptible														
		Ampicillin	Ceftriaxone (meningitis)	Ceftriaxone (non-meningitis)	Clindamycin	Daptomycin	Doxycycline	Erythromycin	Linezolid	Moxifloxacin	Nitrofurantoin*	Oxacillin	Penicillin (meningitis)	Penicillin (non-meningitis)	Tetracycline	Trimethoprim/Sulfa
<i>Enterococcus faecalis</i>	146	98	-	-	-	100	-	100	-	100	-	100	-	28	-	95
<i>Enterococcus faecium</i>	31	18	-	-	-	98	-	86	-	-	-	-	-	-	35	
Methicillin resistant <i>Staphylococcus aureus</i> (MRSA)***	214	-	-	-	62	100	92	19	100	-	0	-	-	85	71	100
Methicillin sensitive <i>Staphylococcus aureus</i> (MSSA)	346	-	-	-	68	100	100	53	100	-	100	-	-	91	96	100
<i>Staphylococcus coagulase-negative</i>	144	-	-	-	75	98	94	-	100	-	46	-	-	-	100	
<i>Streptococcus pneumoniae</i> **	75	-	94	100	84	-	-	60	100	99	-	76	88	74	72	100

Percent Susceptible for each organism/antimicrobial combination was generated by including the first isolate of that organism encountered on a given patient

(-) Drug not tested or drug not indicated

(\*) Tested on urine isolate only (\*\*) Due to low incidence, organism incidence consists of totals from MFSMC, MGSB, MHH, and MUMH combined

(\*\*\*) MRSA rate of the institution was 38% (\*\*\*\*) Based on CLSI M100-32nd Ed breakpoints

<sup>1</sup> Cefazolin (systemic), MIC ≤ 2 µg/mL, susceptible for infections other than uncomplicated UTIs

<sup>2</sup> Cefazolin (urine), MIC ≤ 16 µg/mL, susceptible